GlobeNewsWire
26 Jun 2026, 00:26 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to artificially inflate reported revenue. — Allegations of revenue manipulation directly challenge the integrity of financial statements and top-line growth.
-0.80A securities class action lawsuit alleges ADMA Biologics lacked adequate internal controls and engaged in undisclosed related party transactions. — Poor internal controls and undisclosed conflicts of interest indicate systemic governance failures that increase corporate risk.
-0.60The deadline for investors to move to serve as lead plaintiff in the ADMA Biologics class action is August 10, 2026. — While a procedural deadline, it marks the progression of litigation that could lead to significant financial settlements.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is the subject of a securities class action lawsuit reminder.
The company is facing a securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and inadequate internal controls.
The company is the subject of a securities class action lawsuit reminder.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
